Skip to main content
ENTA logo

Enanta Pharmaceuticals, Inc.

ENTANASDAQHealthcareBiotechnology

$12.00Today:- (-)1Y +8.90%

As of Oct 26, 2026 close

Market cap
$349.08M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$10.20$17.15
Volume (live)
-
Avg. volume (3M)
266.93K

Enanta Pharmaceuticals (ENTA) Financial Ratios

For fiscal 2025 (fiscal year ended Sep 30, 2025), Enanta Pharmaceuticals had return on equity of -84.6% (down from -67.2%), debt-to-equity of 3.11 (up from 1.75), a current ratio of 4.21 (down from 5.21) and return on assets of -16.2% (up from -18.1%). A current ratio of 4.21 means current assets exceed current liabilities.

Enanta Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Valuation Ratios
Forward P/E6.266.266.266.26105.09
P/S Ratio3.923.252.9712.4811.83
P/B Ratio3.951.701.083.352.88
Price/Tangible Book3.951.701.083.352.88
PEG Ratio1.821.821.821.821.82
Enterprise Value Ratios
EV/Revenue3.962.560.939.388.08
Profitability & Returns
Return on Equity (ROE)-84.63%-67.16%-49.74%-33.78%-18.48%
Return on Assets (ROA)-16.23%-18.13%-20.47%-19.01%-14.81%
Return on Invested Capital (ROIC)-92.97%-138.32%-163.29%-94.88%-91.02%
Return on Capital Employed (ROCE)-36.80%-38.10%-34.30%-35.80%-27.20%
Leverage & Solvency Ratios
Debt/Equity3.111.751.030.080.02
Liquidity Ratios
Current Ratio4.215.216.7310.458.82
Quick Ratio4.034.996.5210.008.43
Efficiency Ratios
Asset Turnover0.200.160.190.210.21
Yield & Distribution Ratios
Earnings Yield-32.00%-52.86%-56.90%-11.33%-6.88%
FCF Yield-12.57%-44.06%-47.71%-8.08%-6.16%
Buyback Yield-0.85%-0.90%-1.78%-2.14%-1.16%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Enanta Pharmaceuticals Financial Ratios

What is Enanta Pharmaceuticals's return on equity?

Enanta Pharmaceuticals's return on equity (ROE) was -84.6% for fiscal 2025 (period ended Sep 30, 2025). It was -67.2% a year earlier.

What is Enanta Pharmaceuticals's debt-to-equity ratio?

Enanta Pharmaceuticals's debt-to-equity ratio was 3.11 for fiscal 2025 (period ended Sep 30, 2025). It was 1.75 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition